Guidelines     MGP Ltd

Click here to view the references.

This eLearning module has been funded by Roche Diagnostics Ltd and developed in partnership with Roche Diagnostics Ltd suggested the author for the module and reviewed the module to ensure compliance with appropriate regulations.

The eLearning module, which features case study examples, will be of use to all primary healthcare professionals who encounter adult patients with AF who are or may be at risk of stroke, and who might benefit from introduction of self-monitoring of their anticoagulation status. In order to benefit fully from the eLearning module, it is important to read all the slides and popout links. At the end of the presentation you will find some questions to measure your learning, and a certificate of completion that you can print out and put in your CPD folder.*

Photographs within the eLearning module are for illustration purposes only.

Date of Preparation: June 2015

AAA=abdominal aortic aneurysm; ABPM=ambulatory blood pressure measurement; ACE-I=angiotensin-converting enzyme inhibitor; AF=atrial fibrillation; ALT=alanine transaminase; AST=aspartate aminotransferase; Cr=creatinine; DC=direct current; ECG=electrocardiogram; IHD=ischaemic heart disease; INR=international normalised ratio; LFT=liver function test; NOAC=novel oral anticoagulant; NSAID=non-steroidal anti-inflammatory drug; OTC=over the counter; PAD=peripheral arterial disease; POC=point-of-care; TIA=transient ischaemic attack; TTR=time in therapeutic range; UK NEQAS=UK National External Quality Assessment Service;

* Answer all the questions correctly to generate your CPD certificate.  

The content of this module was developed by Dr Matthew Fay GPwSI cardiology, Westcliffe Medical Centre, Bradford. The case studies included are fictional but based on clinical experience. While every care has been taken to ensure the accuracy of this Guidelines eLearning module, this does not diminish the requirement to exercise clinical judgement and the publishers cannot accept liability for any errors or omissions. 

COAGUCHEK and 'BECAUSE IT'S MY LIFE' are registered trademarks of Roche. 


  1. NICE. Hypertension: clinical management of primary hypertension in adults. Clinical Guideline 127. NICE, 2011. Available at:
  2. NICE. Atrial fibrillation: the management of atrial fibrillation. Clinical Guideline 180. NICE, 2014. Available at:
  3. American College of Cardiology. Atrial Fibrillation Toolkit: diagnosis and risk assessment—HAS-BLED. Available at:
  4. Wolf P, Dawber T, Thomas E, Kannel W. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology 1978; 28: 973–977.
  5. Amdipharm Mercury Company Limited. Marevan 1 mg tablets/warfarin 1 mg tablets. Summary of product characteristics. May 2014.
  6. Bristol-Myers Squibb UK. Eliquis 2.5 mg film-coated tablets. Summary of product characteristics. July 2014.
  7. Boehringer Ingelheim Limited. Pradaxa 110 mg hard capsules. Summary of product characteristics. December 2014.
  8. Bayer HealthCare. Xarelto 15 mg film-coated tablets. Summary of product characteristics. December 2014.
  9. NICE. Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point of care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor). Diagnostics Guidance 14. NICE, 2014. Available at:
  10. Granger C, Alexander J, McMurray J et al, for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. NEJM 2011; 365 (11): 981–992.
  11. Connolly S, Ezekowitz M, Yusuf S et al, and the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 2009; 361 (12): 1139–1151.
  12. Patel M, Mahaffey K, Garg J et al, for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEJM 2011; 365 (10): 883–891.